Synopsis of recent research by authors named "Toru Kondo"
Toru Kondo's recent research has focused on the development of new therapeutic strategies for heart failure and glioblastoma, including the use of an EVA1-antibody drug conjugate to target glioblastoma-initiating cells, which have shown resistance to conventional treatments.
In the realm of cardiology, Kondo has contributed significantly to understanding patient outcomes through the creation of prognostic models, such as the J-PVAD risk score for assessing mortality in patients with cardiogenic shock after Impella implantation and a predictive model for heart failure with preserved ejection fraction (HFpEF).
Kondo's studies also explore the effectiveness of treatments like dapagliflozin across different heart failure phenotypes and genetic analysis in medical contexts, reflecting a multidimensional approach that integrates therapeutic and predictive research.
